Frequency of Ventilator Associated Pneumonia (VAP) in Mechanically Ventilated Patients Using the AnapnoGuard System
Primary Purpose
Ventilator Associated Pneumonia
Status
Completed
Phase
Not Applicable
Locations
Israel
Study Type
Interventional
Intervention
AnapnoGuard 100,
routine mechanical ventilator
Sponsored by
About this trial
This is an interventional prevention trial for Ventilator Associated Pneumonia focused on measuring VAP
Eligibility Criteria
Inclusion Criteria:
- ICU patients;
- Patient was connected to AnapnoGuard system up to six hours from intubation;
- Age - above 18.
Exclusion Criteria:
- Pneumonia;
- Aspiration Pneumonia;
- Chronic or Severe Pneumonia;
- Chronic Obstructive Pulmonary Disease (COPD) requiring permanent home-based antibiotic treatment;
- Interstitial Lung Disease (ILD);
- Post Lung Transplant State;
- Immunosuppression.
- Patients ventilated in prone position
- Patient who was ventilated 3 months prior to being enrolled in the study
- Pregnant women
Sites / Locations
- RAMBAM Medical Center
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
AnapnoGuard 100
Control
Arm Description
Respiratory guard system during mechanical ventilation
routine mechanical ventilator
Outcomes
Primary Outcome Measures
VAP occurence
Secondary Outcome Measures
Adverse events occurence
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT01126320
Brief Title
Frequency of Ventilator Associated Pneumonia (VAP) in Mechanically Ventilated Patients Using the AnapnoGuard System
Official Title
Frequency of Ventilator Associated Pneumonia (VAP) in Mechanically Ventilated ICU Patients Using the AnapnoGuard System
Study Type
Interventional
2. Study Status
Record Verification Date
February 2016
Overall Recruitment Status
Completed
Study Start Date
December 2010 (undefined)
Primary Completion Date
July 2015 (Actual)
Study Completion Date
December 2015 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Hospitech Respiration
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
Ventilator Associated Pneumonia (VAP) is a common complication experienced by mechanically ventilated patients and within the framework of Respiratory Intensive Care Units. The AnapnoGuard system, developed by Hospitech Respiration Ltd. is a ventilation guard system that includes a number of unique characteristics. This study was designed to test the frequency VAP in mechanically ventilated ICU patients using the AnapnoGuard System.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Ventilator Associated Pneumonia
Keywords
VAP
7. Study Design
Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
161 (Actual)
8. Arms, Groups, and Interventions
Arm Title
AnapnoGuard 100
Arm Type
Experimental
Arm Description
Respiratory guard system during mechanical ventilation
Arm Title
Control
Arm Type
Active Comparator
Arm Description
routine mechanical ventilator
Intervention Type
Device
Intervention Name(s)
AnapnoGuard 100,
Intervention Description
Respiratory guard system during mechanical ventilation with routine mechanical ventilator
Intervention Type
Device
Intervention Name(s)
routine mechanical ventilator
Intervention Description
routine mechanical ventilation
Primary Outcome Measure Information:
Title
VAP occurence
Time Frame
2 years
Secondary Outcome Measure Information:
Title
Adverse events occurence
Time Frame
2 years
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
ICU patients;
Patient was connected to AnapnoGuard system up to six hours from intubation;
Age - above 18.
Exclusion Criteria:
Pneumonia;
Aspiration Pneumonia;
Chronic or Severe Pneumonia;
Chronic Obstructive Pulmonary Disease (COPD) requiring permanent home-based antibiotic treatment;
Interstitial Lung Disease (ILD);
Post Lung Transplant State;
Immunosuppression.
Patients ventilated in prone position
Patient who was ventilated 3 months prior to being enrolled in the study
Pregnant women
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Yaron Bar Lavi, Dr.
Organizational Affiliation
RAMBAM Medical Center, Haifa Israel
Official's Role
Principal Investigator
Facility Information:
Facility Name
RAMBAM Medical Center
City
Haifa
Country
Israel
12. IPD Sharing Statement
Learn more about this trial
Frequency of Ventilator Associated Pneumonia (VAP) in Mechanically Ventilated Patients Using the AnapnoGuard System
We'll reach out to this number within 24 hrs